US drugmaker Eli Lilly will sign a $2bn deal with a Hong Kong-listed company that uses AI for drug discovery, according to sources familiar with the matter, highlighting the global pharmaceutical sector’s increasing reliance on medicines developed in China https://ft.trib.al/82KhOJm